• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page
  • Cafepharma also has message boards for retail pharmacies: click here to view

PBM reform advocacy groups

anonymous

Guest
I'm working to build a page on PBM fraud and am looking for resources about PBM reform advocacy groups to link to. Does anyone have any resources or links that I could include?
 




ImmunityBio's Anktiva is being pushed through Medicare Part D instead of its buy and bill channel of Part B.
Medicare will claw this back. This is Medicare fraud. ImmunityBio is in for a rude awakening.
Stay tuned.